HK Stock Market Move | ZYLOXTB(02190) rose more than 3%. The intracranial stent for aneurysm embolization has been approved for market, expected to strengthen the product pipeline layout in the neurointerventional field.

ZYLOXTB (02190) rose by more than 3%, and as of press time, it rose by 2.49% to 25.52 Hong Kong dollars, with a transaction amount of 13.1441 million Hong Kong dollars. On the news front, according to the official WeChat account of ZYLOXTB, recently, TQ Feilong intracranial aneurysm embolization assist stent has been approved by the National Medical Products Administration (NMPA) for listing. It is reported that the TQ Feilong intracranial aneurysm embolization assist stent is mainly used in conjunction with embolic spring coils, specially designed for the treatment of intracranial neurovascular diseases, providing a new efficient solution for clinical diagnosis and treatment. Compared with similar products on the market, the TQ Feilong intracranial aneurysm embolization assist stent has better wall adhesion and imaging properties during surgery, which can improve the visibility and safety of the operation; at the same time, the product models are more complete, meeting the treatment needs of different lesions in clinical practice. China Securities Co., Ltd. stated that the company's spring coil embolization assist stent adopts DFT material weaving technology, which can achieve clear imaging of the entire stent, helping doctors to accurately control the operation throughout the process, improving the visibility and safety of the operation, and the product models are more complete, meeting the treatment needs of different lesions in clinical practice. The approval of the spring coil embolization assist stent is expected to further strengthen the company's product pipeline layout in the field of neurointervention, improve the company's overall solution for neurointervention, help the company increase market share, and maintain a fast-growing trend in performance.